Race enters collaborative preclinical research program with The University of Newcastle to explore use of Bisantrene as a novel FTO directed treatment for melanoma Research designed to identify drug combinations that improve upon current standard of care melanoma treatment with focus on immune checkpoint resistance Project is Race’s first step under Pillar 1 of its Three Pillar strategy, designed to demonstrate Bisantrene’s potential in inhibiting FTO in humans
Race enters collaborative preclinical research program with...
-
- There are more pages in this discussion • 159 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.82 |
Change
-0.005(0.27%) |
Mkt cap ! $309.9M | |||
| Open | High | Low | Value | Volume |
| $1.83 | $1.86 | $1.79 | $157.7K | 86.21K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5623 | $1.79 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.82 | 9999 | 1 |
View Market Depth
| Last trade - 16.10pm 01/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |